Business Context and Reporting Period
Company: Abbott Laboratories (ABT)
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2026
Event: Completion of the acquisition of Exact Sciences Corporation.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain standard periodic financial statements (e.g., revenue, profit, cash flow, or debt levels) for the reporting period.
- Transaction Consideration: $105.00 per share in cash for Exact Sciences common stock.
- Payment Terms: Cash payment without interest, less applicable withholding taxes.
Material Changes
On March 23, 2026, Abbott Laboratories completed the merger with Exact Sciences Corporation pursuant to an Agreement and Plan of Merger dated November 19, 2025. Key details include:
- Exact Sciences is now a direct, wholly owned subsidiary of Abbott Laboratories.
- All outstanding shares of Exact Sciences common stock (excluding certain excluded shares) were converted into the right to receive the cash consideration.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors related to the transaction beyond the standard incorporation by reference of the Merger Agreement. The text notes that the description of the Merger is qualified in its entirety by reference to the full Merger Agreement (Exhibit 2.1).
Investor Verification Checklist
- Verify the total aggregate cash consideration paid by reviewing the number of Exact Sciences shares outstanding at the Effective Time.
- Review the full Merger Agreement (Exhibit 2.1) for details on excluded shares and specific conditions of the merger.
- Check the press release (Exhibit 99.1) for management's strategic rationale and immediate impact statements.
- Monitor subsequent filings (10-Q or 10-K) for the consolidated financial impact of the acquisition on Abbott's balance sheet and liquidity.